Skip to main content

Table 7 Ten-year survival rates of hormone receptors positive (ER+ and/or PR+)/luminal class (including HER2+ cases) based on proliferation assay (Ki-67LI and mitotic scores) and HER2 status

From: Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer

Variable

BCSS

DMFS

 

Number exposed to risk

Number of events

Proportion surviving

Number exposed to risk

Number of events

Proportion surviving

Ki-67LI

      

   Low

295

28

90.5%

295

46

84.4%

   Moderate

250

68

72.8%

249

77

69.7%

   High

95

43

54.7%

94

50

46.8%

Mitotic score

      

   1

324

39

88%

324

58

82%

   2

156

36

77%

155

46

70.3%

   3

226

93

58.8%

225

101

55%

HER2 status

      

   Negative

622

136

78.1%

620

170

72.5%

   Positive

66

29

56%

66

32

51.5%

  1. BCSS, Breast cancer-specific survival; DMFS, distant metastasis-free survival.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us